-transparent.png){kind=logo}
Cefotiam, a new cephalosporin, was evaluated in the treatment of lower respiratory tract infections in 29 patients. The bacteria isolated from the sputum of these patients included Streptococcus pneumoniae (31%), Klebsiella pneumoniae (31%), and Haemophilus influenzae (28%). Satisfactory response was observed in 90% of the patients. There were three treatment failures, two superinfections, and four colonizations with gram-negative organisms resistant to the drug. Superficial phlebitis was noted in two patients. The results of this study suggest that cefotiam is an effective and well-tolerated antibiotic for the treatment of lower respiratory tract infections due to susceptible organisms.
M A Polis, and
C U Tuazon
April 1986,
Singapore medical journal,
M A Polis, and
C U Tuazon
June 1997,
Anales espanoles de pediatria,
M A Polis, and
C U Tuazon
August 1989,
Pharmaceutisch weekblad. Scientific edition,
M A Polis, and
C U Tuazon
July 1989,
Journal of chemotherapy (Florence, Italy),
M A Polis, and
C U Tuazon
May 1981,
Antimicrobial agents and chemotherapy,
M A Polis, and
C U Tuazon
June 1987,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M A Polis, and
C U Tuazon
February 1985,
International journal of clinical pharmacology, therapy, and toxicology,
M A Polis, and
C U Tuazon
December 1980,
CCQ. Critical care quarterly,
M A Polis, and
C U Tuazon
December 2004,
Infectious disease clinics of North America,
